Bluejay Diagnostics (BJDX) Non-Current Deferred Tax Liability (2020 - 2021)
Bluejay Diagnostics (BJDX) posted Non-Current Deferred Tax Liability of $26860.0 for Q4 2021, up 0.79% sequentially from $26649.0 in Q4 2020, and up 0.79% YoY from $26649.0 in Q4 2020.
Bluejay Diagnostics (BJDX) Non-Current Deferred Tax Liability (2020 - 2021) Analysis & Trends
Bluejay Diagnostics has reported Non-Current Deferred Tax Liability for 2 years, with the latest figure at $26860.0 in Q4 2021.
- Quarterly Non-Current Deferred Tax Liability rose 0.79% year-over-year to $26860.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $26860.0 (up 0.79% YoY) and the FY2021 annual result came in at $26860.0, up 0.79% from the prior year.
- Non-Current Deferred Tax Liability advanced to $26860.0 in Q4 2021 per BJDX's latest filing, from $26649.0 in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $26860.0 in Q4 2021 and troughed at $26649.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn |
| 10 | Bluejay Diagnostics | 1.91 Mn | 1.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 26,860.00 |
| Dec 31, 2021 | 26,860.00 |
| Dec 31, 2020 | 26,649.00 |
| Dec 31, 2020 | 26,649.00 |